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Background: LEA Study (GEICAM/2006-11/GBG51), is a randomized clinical trial
comparing bevacizumab in combination with endocrine therapy (ET + B) with
endocrine therapy (ET) in postmenopausal women with advanced or metastatic
HR-positive/HER2-negative breast cancer (BC) with indication of hormonotherapy as
first-line treatment. Patients with secondary hypertension had better progression-free
survival (PFS) and overall survival (OS). We have evaluated the role of two
hypertension-related biomarkers, Angiotensin-Converting Enzyme (ACE) and
Small-Inducible Cytokine B10 (CXCL10) as prognostic and/or predictive biomarkers
of benefit to bevacizumab in the first line metastatic disease.
Methods: From 380 patients, 266 were included in 33 Spanish sites. Median age was 64
years, 63.5% had measurable disease, 97.4% were metastatic at randomization, 51.5%
had visceral disease and 52.6% received previous chemotherapy. PFS was 14.3 months
(range 0.8-61.1), OS was 34 months (range 0.8-71.6) and 93 patients had Objective
Response (OR). We analyzed 124 plasma samples collected before treatment (52 from
ET and 72 from ET + B arms). Circulating levels of ACE and CXCL10 were determined
by ELISA. ACE levels of 115ng/ml and 135ng/ml were pre-defined as cutoff values.
CXCL10 was explored as a quantitative variable.
Results: PFS was 15.1 months (range 1.4-61.1), OS was 31.1 months (range 2.8-61.1)
and 40.3% had OR. OR was significantly different between treatment arms (p < 0.001)
but not PFS or OS. Median ACE concentration was 130.9ng/ml (range 35.3-315.4).
Low ACE (<135ng/ml) had better PFS in the whole population (p = 0.048) and in the
ET + B arm (p = 0.041). ACE cutoff of 115 ng/ml was not able to identify any subgroup
with better prognosis. Median CXCL10 concentration was 230.3pg/ml (range
15.1-4129.6). A higher expression of CXCL10 was significantly associated with worse
OS in the whole population (p < 0.0001) and each treatment arm (p = 0.002 and
p = 0.001 in ET and ET + B, respectively). No association with OR were identified
neither for ACE nor for CXCL10.
Conclusions: ACE levels could be considered a prognostic and a bevacizumab
predictive biomarker of PFS. CXCL10 could be prognostic of OS. Confirmatory studies
are warranted.
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